Skip to main contentSkip to navigation
Sirius Investors

COMBI.ST Stock: CombiGene AB (publ) Stock Price, Analysis & Insights

Get live COMBI.ST stock price $2.47, comprehensive CombiGene AB (publ) stock analysis, charts, news, and expert forecast. Real-time COMBI.ST stock data and investment insights.

2.47
3.89%Today
COMBI.STCombiGene AB (publ) • Stockholm Stock Exchange • Healthcare
Market Cap
48.91M
Volume
8.16K
52W High
3.18
52W Low
1.27

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Headquartered in Lidingö, Sweden, CombiGene AB (publ) was established in 1999 and specializes in pioneering gene therapy solutions for severe, life-altering medical conditions. The company is currently advancing two primary gene therapy candidates in...

Company Information

CEO
Peter Ekolind
Sector
Healthcare
Industry
Biotechnology
Employees
9

Contact Information

Address
Agavagen 52A
Country
SE

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 1.22)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for CombiGene AB (publ) shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for CombiGene AB (publ)
  • Investors should consider how CombiGene AB (publ) fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

48.91M

P/E Ratio (TTM)

-1.09

Beta

1.22

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

43/100 ⭐⭐⭐

Overall
-1.0%
NYSE
-1.6%
NASDAQ
-0.4%
Sector1D1W1MP/EScore
Financial Services+0.3%+1.3%+1.9%19.8
83/100⭐⭐⭐⭐⭐
Technology+0.8%+1.1%+3.0%52.0
76/100⭐⭐⭐⭐⭐
Basic Materials+0.8%+0.3%+1.9%27.9
69/100⭐⭐⭐⭐
Industrials-0.3%-0.9%+2.7%43.0
64/100⭐⭐⭐⭐
Communication Services-0.8%-1.3%+0.4%21.9
48/100⭐⭐⭐
Consumer Defensive+0.6%+1.6%-2.5%31.2
44/100⭐⭐⭐
Healthcare-1.0%-2.0%+1.5%30.5
43/100⭐⭐⭐
Real Estate+0.5%-1.1%-0.0%50.0
33/100⭐⭐
Energy+0.5%-3.6%-0.0%35.9
31/100⭐⭐
Utilities+2.0%-1.3%-5.1%26.1
31/100⭐⭐
Consumer Cyclical-0.3%+0.3%-0.2%55.8
28/100⭐⭐

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-13.